Immudex primarily focuses on the identification of producing large quantities of CD8+ T cells by the means of MHC class I molecules.
In 2011, Immudex received the prestigious “Entrepreneur of the Year 2011” award in the Life Sciences category granted by Ernst & Young.
The award is given to companies not only focused on financial growth, but also for softer values such as the entrepreneur's social responsibility and the ability to aspire an motivate the organization.
Therefore, the study of these lymphocytes in autoimmune diseases and cancer has been difficult, until the fairly recent introduction of MHC multimers.
[6] The Immudex MHC Dextramers, which represent the latest advancement in this field, provide an exponentially greater probability of successful identification of antigen-specific T cells.
The MHC Dextramers covers human, mouse, and monkey alleles that all display disease relevant antigenic peptides.
Though Immudex specializes in MHC Dextramer technology, the company is also pursuing development projects in diagnostics for Lyme disease/Borreliosis, based on the detection of Borrelia-specific T cells in diseased patients.
Knowledge of the level of viral-specific T cells allow evaluation of the patients preparedness for fighting the viral infection and thereby avoid unnecessary antiviral treatment.
CMV infections are often unnoticed by healthy people, but can be life threatening for immune compromised individuals, such as HIV-infected persons and organ-transplant recipients.
The agreement dictates that Immudex will provide MHC-peptide multimers and Elispot proficiency panels to laboratories worldwide, independently of their background and associations.
Immudex, specialized in the detection of antigen-specific T cells has been an active participant in the proficiency panel process and is globally recognized for its expertise in immune monitoring.
Immudex will continue the external validation program established by CIC and CIMT under the successfully implemented harmonization guidelines and will promote a more widespread use of these technologies in the development of new cancer immunotherapies and vaccines against other diseases such as HIV, TB, diabetes and others.